These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
310 related items for PubMed ID: 20736814
1. Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies. McGovern RA, Thielen A, Mo T, Dong W, Woods CK, Chapman D, Lewis M, James I, Heera J, Valdez H, Harrigan PR. AIDS; 2010 Oct 23; 24(16):2517-25. PubMed ID: 20736814 [Abstract] [Full Text] [Related]
2. Population-based sequencing of the V3-loop can predict the virological response to maraviroc in treatment-naive patients of the MERIT trial. McGovern RA, Thielen A, Portsmouth S, Mo T, Dong W, Woods CK, Zhong X, Brumme CJ, Chapman D, Lewis M, James I, Heera J, Valdez H, Harrigan PR. J Acquir Immune Defic Syndr; 2012 Nov 01; 61(3):279-86. PubMed ID: 23095934 [Abstract] [Full Text] [Related]
3. Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients. Swenson LC, Mo T, Dong WW, Zhong X, Woods CK, Jensen MA, Thielen A, Chapman D, Lewis M, James I, Heera J, Valdez H, Harrigan PR. J Infect Dis; 2011 Jan 15; 203(2):237-45. PubMed ID: 21288824 [Abstract] [Full Text] [Related]
5. Correlation between genotypic (V3 population sequencing) and phenotypic (Trofile ES) methods of characterizing co-receptor usage of HIV-1 from 200 treatment-naïve HIV patients screened for Study A4001078. Portsmouth S, Valluri SR, Däumer M, Thiele B, Valdez H, Lewis M, Craig C, Thielen A, James I, Demarest J, Heera J. Antiviral Res; 2013 Jan 15; 97(1):60-5. PubMed ID: 23165088 [Abstract] [Full Text] [Related]
7. Evolution of proviral DNA HIV-1 tropism under selective pressure of maraviroc-based therapy. Baroncelli S, Galluzzo CM, Weimer LE, Pirillo MF, Volpe A, Mercuri A, Cavalli A, Fragola V, Monno L, Degli Antoni A, Ladisa N, Francisci D, Bucciardini R, Floridia M. J Antimicrob Chemother; 2012 Jun 15; 67(6):1479-85. PubMed ID: 22361986 [Abstract] [Full Text] [Related]
8. Use of cellular HIV DNA to predict virologic response to maraviroc: performance of population-based and deep sequencing. Swenson LC, Dong WW, Mo T, Demarest J, Chapman D, Ellery S, Heera J, Valdez H, Poon AF, Harrigan PR. Clin Infect Dis; 2013 Jun 15; 56(11):1659-66. PubMed ID: 23429552 [Abstract] [Full Text] [Related]
13. Maraviroc treatment in non-R5-HIV-1-infected patients results in the selection of extreme CXCR4-using variants with limited effect on the total viral setpoint. McGovern RA, Symons J, Poon AF, Harrigan PR, van Lelyveld SF, Hoepelman AI, van Ham PM, Dong W, Wensing AM, Nijhuis M. J Antimicrob Chemother; 2013 Sep 15; 68(9):2007-14. PubMed ID: 23677920 [Abstract] [Full Text] [Related]
16. Co-receptor switch during HAART is independent of virological success. Saracino A, Monno L, Cibelli DC, Punzi G, Brindicci G, Ladisa N, Tartaglia A, Lagioia A, Angarano G. J Med Virol; 2009 Dec 15; 81(12):2036-44. PubMed ID: 19856465 [Abstract] [Full Text] [Related]
17. Mutations in gp41 are correlated with coreceptor tropism but do not improve prediction methods substantially. Thielen A, Lengauer T, Swenson LC, Dong WW, McGovern RA, Lewis M, James I, Heera J, Valdez H, Harrigan PR. Antivir Ther; 2011 Dec 15; 16(3):319-28. PubMed ID: 21555814 [Abstract] [Full Text] [Related]